Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BIIB067 Administered to Adult Subjects With Amyotrophic Lateral Sclerosis and Confirmed Superoxide Dismutase 1 Mutation

NCT02623699 is registered in ClinicalTrials.gov with Biogen as lead sponsor.

NCT NCT02623699
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02623699 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BIIB067 Administered to Adult Subjects With Amyotrophic Lateral Sclerosis and Confirmed Superoxide Dismutase 1 Mutation
Lead sponsor
Biogen
Phase
Phase 3
Overall status
Completed
Start date
January 20, 2016
Completion date
July 16, 2021
Enrollment
176 (actual)
Sites
40

Conditions

As the registry lists them; a condition with its own page is linked.

amyotrophic lateral sclerosis